Cargando…
miRNA and antisense oligonucleotide-based α-synuclein targeting as disease-modifying therapeutics in Parkinson’s disease
α-synuclein is the synaptic protein majorly involved in neuronal dysfunction and death and it is well known for the last two decades as a hallmark of Parkinson’s disease. Alpha-synuclein is involved in neurodegeneration mediated through various neurotoxic pathways, majorly including autophagy or lys...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9728483/ https://www.ncbi.nlm.nih.gov/pubmed/36506536 http://dx.doi.org/10.3389/fphar.2022.1034072 |
_version_ | 1784845266487083008 |
---|---|
author | Suvarna, Vasanti Deshmukh, Kajal Murahari, Manikanta |
author_facet | Suvarna, Vasanti Deshmukh, Kajal Murahari, Manikanta |
author_sort | Suvarna, Vasanti |
collection | PubMed |
description | α-synuclein is the synaptic protein majorly involved in neuronal dysfunction and death and it is well known for the last two decades as a hallmark of Parkinson’s disease. Alpha-synuclein is involved in neurodegeneration mediated through various neurotoxic pathways, majorly including autophagy or lysosomal dysregulation, mitochondrial disruption, synaptic dysfunction, and oxidative stress. Moreover, the alpha-synuclein aggregation has been associated with the development of several neurodegenerative conditions such as various forms of Parkinson’s disease. The recent discovery in oligonucleotide chemistry has developed potential alpha-synuclein targeting molecules for the treatment of neurodegenerative diseases. The present review article focuses on recent advances in the applications of oligonucleotides acting via alpha-synuclein targeting mechanisms and their implication in combating Parkinson’s disease. Moreover, the article emphasizes the potential of miRNAs, and antisense oligonucleotides and the challenges associated with their use in the therapeutical management of Parkinson’s disease. |
format | Online Article Text |
id | pubmed-9728483 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-97284832022-12-08 miRNA and antisense oligonucleotide-based α-synuclein targeting as disease-modifying therapeutics in Parkinson’s disease Suvarna, Vasanti Deshmukh, Kajal Murahari, Manikanta Front Pharmacol Pharmacology α-synuclein is the synaptic protein majorly involved in neuronal dysfunction and death and it is well known for the last two decades as a hallmark of Parkinson’s disease. Alpha-synuclein is involved in neurodegeneration mediated through various neurotoxic pathways, majorly including autophagy or lysosomal dysregulation, mitochondrial disruption, synaptic dysfunction, and oxidative stress. Moreover, the alpha-synuclein aggregation has been associated with the development of several neurodegenerative conditions such as various forms of Parkinson’s disease. The recent discovery in oligonucleotide chemistry has developed potential alpha-synuclein targeting molecules for the treatment of neurodegenerative diseases. The present review article focuses on recent advances in the applications of oligonucleotides acting via alpha-synuclein targeting mechanisms and their implication in combating Parkinson’s disease. Moreover, the article emphasizes the potential of miRNAs, and antisense oligonucleotides and the challenges associated with their use in the therapeutical management of Parkinson’s disease. Frontiers Media S.A. 2022-11-15 /pmc/articles/PMC9728483/ /pubmed/36506536 http://dx.doi.org/10.3389/fphar.2022.1034072 Text en Copyright © 2022 Suvarna, Deshmukh and Murahari. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Suvarna, Vasanti Deshmukh, Kajal Murahari, Manikanta miRNA and antisense oligonucleotide-based α-synuclein targeting as disease-modifying therapeutics in Parkinson’s disease |
title | miRNA and antisense oligonucleotide-based α-synuclein targeting as disease-modifying therapeutics in Parkinson’s disease |
title_full | miRNA and antisense oligonucleotide-based α-synuclein targeting as disease-modifying therapeutics in Parkinson’s disease |
title_fullStr | miRNA and antisense oligonucleotide-based α-synuclein targeting as disease-modifying therapeutics in Parkinson’s disease |
title_full_unstemmed | miRNA and antisense oligonucleotide-based α-synuclein targeting as disease-modifying therapeutics in Parkinson’s disease |
title_short | miRNA and antisense oligonucleotide-based α-synuclein targeting as disease-modifying therapeutics in Parkinson’s disease |
title_sort | mirna and antisense oligonucleotide-based α-synuclein targeting as disease-modifying therapeutics in parkinson’s disease |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9728483/ https://www.ncbi.nlm.nih.gov/pubmed/36506536 http://dx.doi.org/10.3389/fphar.2022.1034072 |
work_keys_str_mv | AT suvarnavasanti mirnaandantisenseoligonucleotidebasedasynucleintargetingasdiseasemodifyingtherapeuticsinparkinsonsdisease AT deshmukhkajal mirnaandantisenseoligonucleotidebasedasynucleintargetingasdiseasemodifyingtherapeuticsinparkinsonsdisease AT muraharimanikanta mirnaandantisenseoligonucleotidebasedasynucleintargetingasdiseasemodifyingtherapeuticsinparkinsonsdisease |